Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Epigenetic, genetic, and expression analysis of brain-derived neurotrophic factor in Alzheimer's disease (CROSBI ID 726845)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | domaća recenzija

Tudor, Lucija ; Nikolac Perković, Matea ; Babić Leko, Mirjana ; Videtič Paska, Alja ; Kouter, Katarina ; Miloš, Tina ; Nedić Erjavec, Gordana ; Vuić, Barbara ; Konjevod, Marcela ; Šimić, Goran et al. Epigenetic, genetic, and expression analysis of brain-derived neurotrophic factor in Alzheimer's disease // Pharmaca / Mršić-Pelčić, Jasenka ; Vitezić, Dinko ; Janković, Tamara (ur.). 2022. str. 75-75

Podaci o odgovornosti

Tudor, Lucija ; Nikolac Perković, Matea ; Babić Leko, Mirjana ; Videtič Paska, Alja ; Kouter, Katarina ; Miloš, Tina ; Nedić Erjavec, Gordana ; Vuić, Barbara ; Konjevod, Marcela ; Šimić, Goran ; Borovečki, Fran ; Pivac, Nela

engleski

Epigenetic, genetic, and expression analysis of brain-derived neurotrophic factor in Alzheimer's disease

Introduction The most common dementia type is Alzheimer's disease (AD), characterized by progressive cognitive decline and neuronal death, which is often attributed to the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles in the brain. Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays an important role in neurogenesis and neuroplasticity. Therefore, our aim was to investigate the BDNF alternations in AD, at the genetic, epigenetic, and expression levels. Materials and methods The study included 254 patients with AD and mild cognitive impairment (MCI), as a comparative group. Plasma BDNF and cerebrospinal fluid (CSF) Aβ1–42 protein levels were measured with enzyme-linked immunosorbent assay. Quantitative PCR was used to determine the five BDNF gene polymorphisms and BDNF mRNA expression in peripheral white blood cells. The next-generation sequencing was used to determine the methylation status of nine amplicons covering 169 CpG sites in the BDNF gene region. The data were analyzed using GraphPad Prism v4.00 software. Results The results demonstrated increased BDNF plasma concentration in AD patients compared to MCI group, and its positive correlation with Aβ1–42 CSF levels. Tested BDNF polymorphisms were not associated with AD ; however, lower methylation levels, especially in BDNF3 and BDNF9 amplicon region and lower expression of the BDNF gene in peripheral blood were detected in AD patients, compared to MCI subjects. Conclusions These findings could help to elucidate the complex role of BDNF in AD, as well as its potential as an easily accessible peripheral biomarker and novel therapeutic strategy for AD.

Alzheimer's disease ; amyloid-beta1-42 ; brain-derived neurotrophic factor (BDNF) ; BDNF gene polymorphisms ; cerebrospinal fluid ; methylation status ; next generation sequencing ; plasma ; quantitative PCR

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

75-75.

2022.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Pharmaca

Mršić-Pelčić, Jasenka ; Vitezić, Dinko ; Janković, Tamara

Zagreb:

0031-6857

Podaci o skupu

10. hrvatski kongres farmakologije ; 1. hrvatski kongres kliničke farmakologije s međunarodnim sudjelovanjem = 10th Croatian Congress of Pharmacology ; 1st Croatian Congress of Clinical Pharmacology and Therapeutics with International Participation

poster

22.09.2022-25.09.2022

Opatija, Hrvatska

Povezanost rada

Biologija, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje), Kliničke medicinske znanosti, Kognitivna znanost (prirodne, tehničke, biomedicina i zdravstvo, društvene i humanističke znanosti), Temeljne medicinske znanosti